{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:20:56Z","timestamp":1790270456739,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-04973-y","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:27:21Z","timestamp":1773836841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"17","author":[{"given":"Xinyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"6","key":"4973_CR1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/a-1936-3077","volume":"234","author":"G Escherich","year":"2022","unstructured":"Escherich G, Schrappe M. [Updated AWMF Guideline on the Diagnosis and Treatment of Acute Lymphoblastic Leukaemia in Children]. Klin Padiatr. 2022;234(6):363\u20137.","journal-title":"Klin Padiatr"},{"issue":"2","key":"4973_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11899-014-0210-9","volume":"9","author":"H Dombret","year":"2014","unstructured":"Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. 2014;9(2):158\u201364.","journal-title":"Curr Hematol Malig Rep"},{"key":"4973_CR3","doi-asserted-by":"crossref","unstructured":"Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016;91(11):1645-66.","DOI":"10.1016\/j.mayocp.2016.09.010"},{"issue":"24","key":"4973_CR4","doi-asserted-by":"publisher","first-page":"21978","DOI":"10.1002\/cam4.6771","volume":"12","author":"M Gu","year":"2023","unstructured":"Gu M, Xia Y, Zhang J, Tang Y, Xu W, Song H, et al. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing. Cancer Med. 2023;12(24):21978\u201384.","journal-title":"Cancer Med"},{"issue":"20","key":"4973_CR5","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","volume":"30","author":"J Holowiecki","year":"2012","unstructured":"Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30(20):2441\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4973_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.bmt.1705556","volume":"39","author":"M Markova","year":"2007","unstructured":"Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, et al. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone Marrow Transpl. 2007;39(4):193\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"4973_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1042819021000054670","volume":"44","author":"KU Chow","year":"2003","unstructured":"Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, et al. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma. 2003;44(1):165\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4973_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12885-019-5464-0","volume":"19","author":"M Jin","year":"2019","unstructured":"Jin M, Hu Y, Wu W, Luo Y, Tan Y, Yu J, et al. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. BMC Cancer. 2019;19(1):242.","journal-title":"BMC Cancer"},{"issue":"10","key":"4973_CR9","first-page":"827","volume":"40","author":"H Ai","year":"2019","unstructured":"Ai H, Fu YW, Wang YQ, Wei XD, Song YP. [Clinical observation of 12 patients with refractory\/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(10):827\u201330.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"4973_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-024-00982-3","volume":"14","author":"YY Li","year":"2024","unstructured":"Li YY, Ge SS, Huang YH, Xu MZ, Wan CL, Tan KW, et al. Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed\/refractory acute myeloid leukemia: results of a pilot study. Blood Cancer J. 2024;14(1):12.","journal-title":"Blood Cancer J"},{"issue":"12","key":"4973_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"4973_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15(3):367\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"4973_CR13","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55(6):1114\u201325.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"4973_CR14","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6(10):1562\u20138.","journal-title":"J Clin Oncol"},{"key":"4973_CR15","doi-asserted-by":"publisher","first-page":"8212286","DOI":"10.1155\/2022\/8212286","volume":"2022","author":"F Wang","year":"2022","unstructured":"Wang F, Xie M, Chen P, Wang D, Yang M. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism. Oxid Med Cell Longev. 2022;2022:8212286.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"4973_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MPH.0000000000002055","volume":"43","author":"K Yalcin","year":"2021","unstructured":"Yalcin K, Pehlivan B, Celen S, Bas EG, Kabakci C, Pashayev D, et al. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol. 2021;43(7):266\u201370.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"4973_CR17","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1038\/s41375-022-01693-z","volume":"36","author":"A Eichinger","year":"2022","unstructured":"Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, et al. Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. Leukemia. 2022;36(11):2567\u201376.","journal-title":"Leukemia"},{"issue":"4","key":"4973_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021;39(4):295\u2013307.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4973_CR19","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood.2021013290","volume":"139","author":"MR Gaballa","year":"2022","unstructured":"Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022;139(12):1908\u201319.","journal-title":"Blood"},{"key":"4973_CR20","first-page":"421723","volume":"2014","author":"M Bar","year":"2014","unstructured":"Bar M, Wood BL, Radich JP, Doney KC, Woolfrey AE, Delaney C, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treat. 2014;2014:421723.","journal-title":"Leuk Res Treat"},{"issue":"2","key":"4973_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","volume":"120","author":"W Leung","year":"2012","unstructured":"Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468\u201372.","journal-title":"Blood"},{"issue":"12","key":"4973_CR22","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/s41375-022-01714-x","volume":"36","author":"M Thastrup","year":"2022","unstructured":"Thastrup M, Duguid A, Mirian C, Schmiegelow K, Halsey C. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia. 2022;36(12):2751\u201368.","journal-title":"Leukemia"},{"issue":"7","key":"4973_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","volume":"19","author":"LM Poon","year":"2013","unstructured":"Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19(7):1059\u201364.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"4973_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12185-024-03710-6","volume":"119","author":"H Ueki","year":"2024","unstructured":"Ueki H, Ogawa C, Goto H, Nishi M, Yamanaka J, Mochizuki S, et al. TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia. Int J Hematol. 2024;119(4):450\u20138.","journal-title":"Int J Hematol"},{"issue":"3","key":"4973_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-023-03701-z","volume":"119","author":"M Yanagi","year":"2024","unstructured":"Yanagi M, Mori M, Honda M, Mitani Y, Seki M, Fukuoka K, et al. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma. Int J Hematol. 2024;119(3):327\u201333.","journal-title":"Int J Hematol"},{"issue":"1","key":"4973_CR26","doi-asserted-by":"publisher","first-page":"e70026","DOI":"10.1002\/hon.70026","volume":"43","author":"H Morokawa","year":"2025","unstructured":"Morokawa H, Hirabayashi K, Furui Y, Okura E, Saito S, Nakazawa Y. Long-Term Outcomes of Reduced-Toxicity Conditioning Using 8-Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies. Hematol Oncol. 2025;43(1):e70026.","journal-title":"Hematol Oncol"},{"issue":"3","key":"4973_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/10428194.2019.1672060","volume":"61","author":"M Molica","year":"2020","unstructured":"Molica M, Breccia M, Capria S, Trisolini S, Foa R, Jabbour E, et al. The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leuk Lymphoma. 2020;61(3):536\u201345.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"4973_CR28","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1038\/s41409-020-0806-8","volume":"55","author":"F Saglio","year":"2020","unstructured":"Saglio F, Zecca M, Pagliara D, Giorgiani G, Balduzzi A, Calore E, et al. Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transpl. 2020;55(10):1918\u201327.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"4973_CR29","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/leu.2009.30","volume":"23","author":"JE Rubnitz","year":"2009","unstructured":"Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009;23(8):1410\u20136.","journal-title":"Leukemia"},{"issue":"17","key":"4973_CR30","doi-asserted-by":"publisher","first-page":"e0228","DOI":"10.1097\/MD.0000000000010228","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang J, Zhao J, Fei X, Yin Y, Cheng H, Zhang W, et al. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Med (Baltim). 2018;97(17):e0228.","journal-title":"Med (Baltim)"},{"issue":"11","key":"4973_CR31","doi-asserted-by":"publisher","first-page":"101345","DOI":"10.1016\/j.cpcardiol.2022.101345","volume":"47","author":"SE Janus","year":"2022","unstructured":"Janus SE, Heisler AC, Al Jammal M, Chahine N, Chami T, Hajjari J, et al. Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database. Curr Probl Cardiol. 2022;47(11):101345.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"4973_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553\u201360.","journal-title":"Blood"},{"issue":"8","key":"4973_CR33","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(8):e552\u201361.","journal-title":"Lancet Haematol"},{"issue":"1","key":"4973_CR34","doi-asserted-by":"publisher","first-page":"14135","DOI":"10.1038\/s41598-019-50509-1","volume":"9","author":"A Poczta","year":"2019","unstructured":"Poczta A, Rogalska A, Lukawska M, Marczak A. Antileukemic activity of novel adenosine derivatives. Sci Rep. 2019;9(1):14135.","journal-title":"Sci Rep"},{"issue":"6","key":"4973_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3109\/10428194.2012.741233","volume":"54","author":"A Wolska","year":"2013","unstructured":"Wolska A, Cebula-Obrzut B, Smolewski P, Robak T. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. Leuk Lymphoma. 2013;54(6):1268\u201378.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"4973_CR36","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1182\/blood.V118.21.3072.3072","volume":"118","author":"Y Zhou","year":"2011","unstructured":"Zhou Y, Jorgensen JL, Saliba RM, Wang SA, Rondon G, Ledesma C, et al. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood. 2011;118(21):3072.","journal-title":"Blood"},{"issue":"1","key":"4973_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","volume":"57","author":"G Heinze","year":"2001","unstructured":"Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57(1):114\u20139.","journal-title":"Biometrics"},{"issue":"2","key":"4973_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","volume":"59","author":"A Spyridonidis","year":"2024","unstructured":"Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024;59(2):217\u201323.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"4973_CR39","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021;39(7):768\u201378.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4973_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00277-023-05557-z","volume":"103","author":"H Ishida","year":"2024","unstructured":"Ishida H, Arakawa Y, Hasegawa D, Usami I, Hashii Y, Arai Y, et al. Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2024;103(3):843\u201354.","journal-title":"Ann Hematol"},{"key":"4973_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fped.2020.00454","volume":"8","author":"JJ Boelens","year":"2020","unstructured":"Boelens JJ, Hosszu KK, Nierkens S. Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization. Front Pediatr. 2020;8:454.","journal-title":"Front Pediatr"},{"issue":"17","key":"4973_CR42","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","volume":"7","author":"NP Buxbaum","year":"2023","unstructured":"Buxbaum NP, Soci\u00e9 G, Hill GR, MacDonald KPA, Tkachev V, Teshima T, et al. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD. Blood Adv. 2023;7(17):4886\u2013902.","journal-title":"Blood Adv"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04973-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:05:28Z","timestamp":1777262728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04973-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4973"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04973-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol \u2018The impact of cladribine-based conditioning regimens on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for childhood acute leukemia\u2019 was approved by the\n                      Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University\n                      (SYSKY-2024-025-01) on 16 Jan 2024. This study was conducted in accordance with the Declaration of Helsinki. The protocol, amendments, and informed consent forms were approved by the appropriate institutional review board and independent ethics committee before the study began. This study was a retrospective clinical study and received an informed consent exemption approved by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}